Revenio Group Corporation: Transfer of the Company’s own shares

Revenio Group Corporation, Stock Exchange Release, May 16, 2019 at 15.00

Transfer of the Company's own shares 

Revenio Group Corporation has transferred on May 13, 2019 3,029 shares (REG1V) to the members of the Board of Directors as part of remuneration of the Board.

Revenio Group Corporation's AGM decided on March 20, 2019 that 40% of the fee paid to a board member should be paid in company shares while 60% will comprise a monetary payment. The AGM decided that the Chair of the Board be entitled to an annual emolument of EUR 48,000 and the other Board members to an annual emolument of EUR 24,000. The share payment will be valued using the weighted average value of the share on the day following the release of the Interim Report January 1- March 31, 2019.

As a result of these transfers, the share-based board member fees have been completely settled for the year 2019. Revenio Group Corporation now holds a total of 53,184 of its own shares.

Revenio Group Corporation

For further information, please contact:

Timo Hildén, CEO, tel.  +358 40 580 4774

timo.hilden@revenio.fi

www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

 www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology.

The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. Revenio’s core business is to develop and commercialize effective and easily adopted devices to assist in the diagnostics of glaucoma and its monitoring during treatment.

Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio’s technology is on the early detection of glaucoma, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.

Subscribe